APO Research
Talk to an analyst

APO RESEARCH · REPORT

OTC Anti-Infective Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global OTC Anti-Infective Drug Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchOTC Anti-Infective Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal OTC Anti-Infective Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal OTC Anti-Infective Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OTC Anti-Infective Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal OTC Anti-Infective Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global OTC Anti-Infective Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for OTC Anti-Infective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for OTC Anti-Infective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for OTC Anti-Infective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for OTC Anti-Infective Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of OTC Anti-Infective Drug include Cipla, CR SANJIU, Lingrui, Sun Pharma, Bayer, GSK, MYLAN, NOVARTIS and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for OTC Anti-Infective Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of OTC Anti-Infective Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for OTC Anti-Infective Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the OTC Anti-Infective Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global OTC Anti-Infective Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for OTC Anti-Infective Drug revenue, projected growth trends, production technology, application and end-user industry.

OTC Anti-Infective Drug Segment by Company

Cipla

CR SANJIU

Lingrui

Sun Pharma

Bayer

GSK

MYLAN

NOVARTIS

Johnson & Johnson

Teva

OTC Anti-Infective Drug Segment by Type

Antiviral

Antibacterial

Antifungal

Antiseptics

Other

OTC Anti-Infective Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

OTC Anti-Infective Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of OTC Anti-Infective Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of OTC Anti-Infective Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, OTC Anti-Infective Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global OTC Anti-Infective Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antiviral Major Player Table 3. Antibacterial Major Player Table 4. Antifungal Major Player Table 5. Antiseptics Major Player Table 6. Other Major Player Table 7. Global OTC Anti-Infective Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacies Major Player Table 9. Online Pharmacies Major Player Table 10. Hospital Pharmacies Major Player Table 11. OTC Anti-Infective Drug Industry Trends Table 12. OTC Anti-Infective Drug Industry Drivers Table 13. OTC Anti-Infective Drug Industry Opportunities and Challenges Table 14. OTC Anti-Infective Drug Industry Restraints Table 15. Global OTC Anti-Infective Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global OTC Anti-Infective Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global OTC Anti-Infective Drug Market Share by Region (2021-2026) Table 18. Global OTC Anti-Infective Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global OTC Anti-Infective Drug Market Share by Region (2027-2032) Table 20. Global OTC Anti-Infective Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global OTC Anti-Infective Drug Revenue Market Share by Players (2021-2026) Table 22. Global OTC Anti-Infective Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global OTC Anti-Infective Drug Key Players Headquarters & Area Served Table 24. Global OTC Anti-Infective Drug Players, Product Type & Application Table 25. Global OTC Anti-Infective Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global OTC Anti-Infective Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global OTC Anti-Infective Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global OTC Anti-Infective Drug Revenue Market Share by Type (2021-2026) Table 32. Global OTC Anti-Infective Drug Revenue Market Share by Type (2027-2032) Table 33. Global OTC Anti-Infective Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global OTC Anti-Infective Drug Revenue Market Share by Application (2021-2026) Table 37. Global OTC Anti-Infective Drug Revenue Market Share by Application (2027-2032) Table 38. Cipla Company Information Table 39. Cipla Business Overview Table 40. Cipla OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Cipla OTC Anti-Infective Drug Product Portfolio Table 42. Cipla Recent Development Table 43. CR SANJIU Company Information Table 44. CR SANJIU Business Overview Table 45. CR SANJIU OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. CR SANJIU OTC Anti-Infective Drug Product Portfolio Table 47. CR SANJIU Recent Development Table 48. Lingrui Company Information Table 49. Lingrui Business Overview Table 50. Lingrui OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Lingrui OTC Anti-Infective Drug Product Portfolio Table 52. Lingrui Recent Development Table 53. Sun Pharma Company Information Table 54. Sun Pharma Business Overview Table 55. Sun Pharma OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Sun Pharma OTC Anti-Infective Drug Product Portfolio Table 57. Sun Pharma Recent Development Table 58. Bayer Company Information Table 59. Bayer Business Overview Table 60. Bayer OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Bayer OTC Anti-Infective Drug Product Portfolio Table 62. Bayer Recent Development Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. GSK OTC Anti-Infective Drug Product Portfolio Table 67. GSK Recent Development Table 68. MYLAN Company Information Table 69. MYLAN Business Overview Table 70. MYLAN OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. MYLAN OTC Anti-Infective Drug Product Portfolio Table 72. MYLAN Recent Development Table 73. NOVARTIS Company Information Table 74. NOVARTIS Business Overview Table 75. NOVARTIS OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. NOVARTIS OTC Anti-Infective Drug Product Portfolio Table 77. NOVARTIS Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Johnson & Johnson OTC Anti-Infective Drug Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Teva Company Information Table 84. Teva Business Overview Table 85. Teva OTC Anti-Infective Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Teva OTC Anti-Infective Drug Product Portfolio Table 87. Teva Recent Development Table 88. North America OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 89. North America OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 90. North America OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 91. North America OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 92. North America OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America OTC Anti-Infective Drug Revenue by Country (2021-2026) & (US$ Million) Table 94. North America OTC Anti-Infective Drug Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe OTC Anti-Infective Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe OTC Anti-Infective Drug Revenue by Country (US$ Million) & (2027-2032) Table 102. China OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. China OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. China OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. China OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia OTC Anti-Infective Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia OTC Anti-Infective Drug Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia OTC Anti-Infective Drug Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA OTC Anti-Infective Drug Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA OTC Anti-Infective Drug Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA OTC Anti-Infective Drug Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA OTC Anti-Infective Drug Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA OTC Anti-Infective Drug Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA OTC Anti-Infective Drug Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. OTC Anti-Infective Drug Image Figure 2. Global OTC Anti-Infective Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OTC Anti-Infective Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antiviral Image Figure 5. Antibacterial Image Figure 6. Antifungal Image Figure 7. Antiseptics Image Figure 8. Other Image Figure 9. Global OTC Anti-Infective Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global OTC Anti-Infective Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Hospital Pharmacies Image Figure 14. Global OTC Anti-Infective Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global OTC Anti-Infective Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global OTC Anti-Infective Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global OTC Anti-Infective Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global OTC Anti-Infective Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global OTC Anti-Infective Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global OTC Anti-Infective Drug Revenue Market Share by Type (2021-2032) Figure 22. Global OTC Anti-Infective Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global OTC Anti-Infective Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global OTC Anti-Infective Drug Revenue Market Share by Application (2021-2032) Figure 25. North America OTC Anti-Infective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America OTC Anti-Infective Drug Revenue Share by Type (2021-2032) Figure 27. North America OTC Anti-Infective Drug Revenue Share by Application (2021-2032) Figure 28. North America OTC Anti-Infective Drug Revenue Share by Country (2021-2032) Figure 29. United States OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe OTC Anti-Infective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe OTC Anti-Infective Drug Revenue Share by Type (2021-2032) Figure 34. Europe OTC Anti-Infective Drug Revenue Share by Application (2021-2032) Figure 35. Europe OTC Anti-Infective Drug Revenue Share by Country (2021-2032) Figure 36. Germany OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China OTC Anti-Infective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China OTC Anti-Infective Drug Revenue Share by Type (2021-2032) Figure 46. China OTC Anti-Infective Drug Revenue Share by Application (2021-2032) Figure 47. Asia OTC Anti-Infective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia OTC Anti-Infective Drug Revenue Share by Type (2021-2032) Figure 49. Asia OTC Anti-Infective Drug Revenue Share by Application (2021-2032) Figure 50. Asia OTC Anti-Infective Drug Revenue Share by Region (2021-2032) Figure 51. Japan OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA OTC Anti-Infective Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA OTC Anti-Infective Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA OTC Anti-Infective Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA OTC Anti-Infective Drug Revenue Share by Country (2021-2032) Figure 61. Brazil OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt OTC Anti-Infective Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
  • Antiseptics
  • Other
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Cipla
  • CR SANJIU
  • Lingrui
  • Sun Pharma
  • Bayer
  • GSK
  • MYLAN
  • NOVARTIS
  • Johnson & Johnson
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 OTC Anti-Infective Drug Market by Type
  3. 1.2.1 Global OTC Anti-Infective Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antiviral
  5. 1.2.3 Antibacterial
  6. 1.2.4 Antifungal
  7. 1.2.5 Antiseptics
  8. 1.2.6 Other
  9. 1.3 OTC Anti-Infective Drug Market by Application
  10. 1.3.1 Global OTC Anti-Infective Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Hospital Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 OTC Anti-Infective Drug Market Dynamics
  1. 2.1 OTC Anti-Infective Drug Industry Trends
  2. 2.2 OTC Anti-Infective Drug Industry Drivers
  3. 2.3 OTC Anti-Infective Drug Industry Opportunities and Challenges
  4. 2.4 OTC Anti-Infective Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global OTC Anti-Infective Drug Market Perspective (2021-2032)
  2. 3.2 Global OTC Anti-Infective Drug Growth Trends by Region
  3. 3.2.1 Global OTC Anti-Infective Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global OTC Anti-Infective Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global OTC Anti-Infective Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global OTC Anti-Infective Drug Revenue by Players
  2. 4.1.1 Global OTC Anti-Infective Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global OTC Anti-Infective Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global OTC Anti-Infective Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global OTC Anti-Infective Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global OTC Anti-Infective Drug Key Players Headquarters & Area Served
  7. 4.4 Global OTC Anti-Infective Drug Players, Product Type & Application
  8. 4.5 Global OTC Anti-Infective Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global OTC Anti-Infective Drug Market CR5 and HHI
  11. 4.6.3 2025 OTC Anti-Infective Drug Tier 1, Tier 2, and Tier 3
5 OTC Anti-Infective Drug Market Size by Type
  1. 5.1 Global OTC Anti-Infective Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 5.3 Global OTC Anti-Infective Drug Revenue Market Share by Type (2021-2032)
6 OTC Anti-Infective Drug Market Size by Application
  1. 6.1 Global OTC Anti-Infective Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global OTC Anti-Infective Drug Revenue by Application (2021-2032)
  3. 6.3 Global OTC Anti-Infective Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cipla
  2. 7.1.1 Cipla Company Information
  3. 7.1.2 Cipla Business Overview
  4. 7.1.3 Cipla OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cipla OTC Anti-Infective Drug Product Portfolio
  6. 7.1.5 Cipla Recent Developments
  7. 7.2 CR SANJIU
  8. 7.2.1 CR SANJIU Company Information
  9. 7.2.2 CR SANJIU Business Overview
  10. 7.2.3 CR SANJIU OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CR SANJIU OTC Anti-Infective Drug Product Portfolio
  12. 7.2.5 CR SANJIU Recent Developments
  13. 7.3 Lingrui
  14. 7.3.1 Lingrui Company Information
  15. 7.3.2 Lingrui Business Overview
  16. 7.3.3 Lingrui OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lingrui OTC Anti-Infective Drug Product Portfolio
  18. 7.3.5 Lingrui Recent Developments
  19. 7.4 Sun Pharma
  20. 7.4.1 Sun Pharma Company Information
  21. 7.4.2 Sun Pharma Business Overview
  22. 7.4.3 Sun Pharma OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sun Pharma OTC Anti-Infective Drug Product Portfolio
  24. 7.4.5 Sun Pharma Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer OTC Anti-Infective Drug Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 GSK
  32. 7.6.1 GSK Company Information
  33. 7.6.2 GSK Business Overview
  34. 7.6.3 GSK OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GSK OTC Anti-Infective Drug Product Portfolio
  36. 7.6.5 GSK Recent Developments
  37. 7.7 MYLAN
  38. 7.7.1 MYLAN Company Information
  39. 7.7.2 MYLAN Business Overview
  40. 7.7.3 MYLAN OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MYLAN OTC Anti-Infective Drug Product Portfolio
  42. 7.7.5 MYLAN Recent Developments
  43. 7.8 NOVARTIS
  44. 7.8.1 NOVARTIS Company Information
  45. 7.8.2 NOVARTIS Business Overview
  46. 7.8.3 NOVARTIS OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 NOVARTIS OTC Anti-Infective Drug Product Portfolio
  48. 7.8.5 NOVARTIS Recent Developments
  49. 7.9 Johnson & Johnson
  50. 7.9.1 Johnson & Johnson Company Information
  51. 7.9.2 Johnson & Johnson Business Overview
  52. 7.9.3 Johnson & Johnson OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Johnson & Johnson OTC Anti-Infective Drug Product Portfolio
  54. 7.9.5 Johnson & Johnson Recent Developments
  55. 7.10 Teva
  56. 7.10.1 Teva Company Information
  57. 7.10.2 Teva Business Overview
  58. 7.10.3 Teva OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva OTC Anti-Infective Drug Product Portfolio
  60. 7.10.5 Teva Recent Developments
8 North America
  1. 8.1 North America OTC Anti-Infective Drug Revenue (2021-2032)
  2. 8.2 North America OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America OTC Anti-Infective Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America OTC Anti-Infective Drug Revenue by Type (2027-2032)
  5. 8.3 North America OTC Anti-Infective Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America OTC Anti-Infective Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America OTC Anti-Infective Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America OTC Anti-Infective Drug Revenue by Application (2027-2032)
  9. 8.5 North America OTC Anti-Infective Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America OTC Anti-Infective Drug Revenue by Country
  11. 8.6.1 North America OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America OTC Anti-Infective Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America OTC Anti-Infective Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe OTC Anti-Infective Drug Revenue (2021-2032)
  2. 9.2 Europe OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe OTC Anti-Infective Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe OTC Anti-Infective Drug Revenue by Type (2027-2032)
  5. 9.3 Europe OTC Anti-Infective Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe OTC Anti-Infective Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe OTC Anti-Infective Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe OTC Anti-Infective Drug Revenue by Application (2027-2032)
  9. 9.5 Europe OTC Anti-Infective Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe OTC Anti-Infective Drug Revenue by Country
  11. 9.6.1 Europe OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe OTC Anti-Infective Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe OTC Anti-Infective Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China OTC Anti-Infective Drug Revenue (2021-2032)
  2. 10.2 China OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 10.2.1 China OTC Anti-Infective Drug Revenue by Type (2021-2026)
  4. 10.2.2 China OTC Anti-Infective Drug Revenue by Type (2027-2032)
  5. 10.3 China OTC Anti-Infective Drug Revenue Share by Type (2021-2032)
  6. 10.4 China OTC Anti-Infective Drug Revenue by Application (2021-2032)
  7. 10.4.1 China OTC Anti-Infective Drug Revenue by Application (2021-2026)
  8. 10.4.2 China OTC Anti-Infective Drug Revenue by Application (2027-2032)
  9. 10.5 China OTC Anti-Infective Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia OTC Anti-Infective Drug Revenue (2021-2032)
  2. 11.2 Asia OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia OTC Anti-Infective Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia OTC Anti-Infective Drug Revenue by Type (2027-2032)
  5. 11.3 Asia OTC Anti-Infective Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia OTC Anti-Infective Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia OTC Anti-Infective Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia OTC Anti-Infective Drug Revenue by Application (2027-2032)
  9. 11.5 Asia OTC Anti-Infective Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia OTC Anti-Infective Drug Revenue by Country
  11. 11.6.1 Asia OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia OTC Anti-Infective Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia OTC Anti-Infective Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA OTC Anti-Infective Drug Revenue (2021-2032)
  2. 12.2 SAMEA OTC Anti-Infective Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA OTC Anti-Infective Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA OTC Anti-Infective Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA OTC Anti-Infective Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA OTC Anti-Infective Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA OTC Anti-Infective Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA OTC Anti-Infective Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA OTC Anti-Infective Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA OTC Anti-Infective Drug Revenue by Country
  11. 12.6.1 SAMEA OTC Anti-Infective Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA OTC Anti-Infective Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA OTC Anti-Infective Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst